Navigation Links
Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial
Date:9/1/2010

the overall MIVI-TRUST program to the global retina community at a number of major international ophthalmology congresses. Given the success of the overall Phase III clinical program, I am extremely confident that microplasmin has the potential to provide both patients and retina specialists with a highly attractive treatment option for a broad range of retinal disorders."

Dr. J. Michael Jumper, commenting on his presentation at the ASRS, said, "These results confirm microplasmin's potential to treat patients with macular disease caused by vitreous traction, including full thickness macular hole (a condition which currently requires major eye surgery to prevent irreversible vision loss), with a single intravitreal injection, a very appealing option when compared to surgery."

16th Annual Gertrude D. Pyron Award for Outstanding Achievement in Retina Research

Dr. Julia Haller (Ophthalmologist-in-Chief, Wills Eye Institute, and Professor and Chair of Department of Ophthalmology of Thomas Jefferson University, Philadelphia), was presented with the 16th Annual Gertrude D. Pyron Award for Outstanding Achievement in Retina Research at ASRS. At the meeting, she chose to discuss microplasmin as a treatment option for retinal diseases in the Pyron Lecture entitled, "Ties That Bind: The Vitreo-Retinal Relationship." The lecture, which took place on August 29, centered on the positive results of the microplasmin Phase III program, with particular focus on the wealth of new information about the vitreoretinal interface that the MIVI-TRUST program has generated and its implications for the vitreoretinal surgeon.

Notes to Editors

About Focal Vitreomacular Adhesion (VMA)

Focal vitreomacular adhesion is a condition in which the vitreous gel, in the center of the eye, has an abnormally strong adhesion to the macula, the center of the retina at the back of the eye. Vitreomacular adhesion plays a key role in nu
'/>"/>

SOURCE ThromboGenics NV
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. ThromboGenics - Positive Microplasmin Phase II Data Published in Ophthalmology
2. ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
3. Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
4. Resverlogix Phase 1b/2a Study Meets Primary Endpoint
5. SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
6. Xceed Meets HTX/CIHR Grant Milestone: Decreasing Sample-Prep Time From Days to Less Than Eight Hours
7. Orexigen(R) Therapeutics Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints
8. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
9. Zemea Propanediol Meets U.S. Environmental Protection Agency Design for the Environment Criteria
10. Anesiva Phase 3 Trial of Adlea Meets Primary Endpoint to Significantly Reduce Pain After Total Knee Replacement Surgery
11. Human Genome Sciences Announces Albuferon(R) Meets Primary Endpoint in Phase 3 Trial in Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... PA (PRWEB) April 17, 2015 ... a leader in regulatory data management, preparation, and submission ... today the availability of a new Lot Distribution Report ... are required to remain compliant with the FDA’s new ... by the FDA to monitor the volume and timing ...
(Date:4/17/2015)... , April 17, 2015  US-Australian drug discovery ... a Memorandum of Understanding with the Feinstein Institute ... New York to collaborate with the ... The collaboration brings together the drug ... clinical expertise of the Feinstein Institute in neurosciences ...
(Date:4/16/2015)... Spirax Sarco, the leader in ... newly designed, state-of-the-art website in the first quarter ... promotes the Spirax Sarco brand, company capabilities, and ... a site visitor might be looking for including ... serviced, the latest company news, careers, and much ...
(Date:4/16/2015)... April 16, 2015 Capillus, LLC ... and physician network in Europe and Asia. The ... appointed Fernando Bermúdez, former Business Development Director of ... industry veteran, Mr. Bermúdez’s professional achievements include increasing ... Spain, while also penetrating the Portuguese marketplace with ...
Breaking Biology Technology:Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 2Reed Tech Announces FDA Lot Distribution Report (LDR) Service for Manufacturers of Biologic Products 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6Spirax Sarco website has a new look 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2
... Inc. (Nasdaq: VVUS ), a biopharmaceutical company ... today reported its highlights and financial results for the third ... Quarter Highlights , In the third quarter of ... pivotal 56-week studies, EQUIP (OB-302) and CONQUER (OB-303), evaluating the ...
... Nov. 3 Sangamo BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of Sangamo,s ZFP Therapeutic(TM) ... at 2:20 pm ET on Tuesday, November 10, 2009 at ... be held in New York City. , The presentation will ...
... WILMINGTON, Delaware, November 3 The ... Technologies Market, (2009 - 2014),published by MarketsandMarkets ( ... stem cell market. It identifies and analyzes,the main ... services, technologies, and applications submarkets in different,geographic regions. ...
Cached Biology Technology:VIVUS Reports Third Quarter 2009 Highlights and Financial Results 2VIVUS Reports Third Quarter 2009 Highlights and Financial Results 3VIVUS Reports Third Quarter 2009 Highlights and Financial Results 4VIVUS Reports Third Quarter 2009 Highlights and Financial Results 5VIVUS Reports Third Quarter 2009 Highlights and Financial Results 6VIVUS Reports Third Quarter 2009 Highlights and Financial Results 7VIVUS Reports Third Quarter 2009 Highlights and Financial Results 8Sangamo BioSciences Announces Presentation at Merriman Curhan Ford's Investor Summit 2009 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3
(Date:4/2/2015)... -- Fingerprint Cards (FPC) has received an ... distributor World Peace Industrial Group (WPI), part of WPG ... major part of the shipments will take place during ... manufacturers in China . The order ... revenue guidance of + 1 000 MSEK for 2015.  ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/31/2015)... 31, 2015   Guidepoint , a leading global ... Post-Surgical Pain Management TRACKER, part of the Guidepoint ... in the medical device and therapeutics markets. The Post-Surgical ... treatment volumes, market share, and adoption rates across three ... joint surgery. The Post-Surgical Pain Management TRACKER ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3
... the dead bone of a transplanted skeletal graft into living ... gene therapy to stimulate the body into treating the foreign ... thousands of cancer and trauma patients each year who suffer ... online Feb. 13 and will appear in the March 1 ...
... Malignancies Program at the H. Lee Moffitt Cancer Center ... of the experimental drug Revlimid showing promise as an ... a form of pre-leukemia. Given in pill form, Revlimid ... nourish tumors (anti-angiogenesis) and stimulates the immune system to ...
... many years, DNA and proteins have been,viewed as ... with RNA seen,as little more than a messenger ... Whitehead Institute for Biomedical Research,and Massachusetts Institute of ... regulate thousands of human genes--more,than one third of ...
Cached Biology News:Gene therapy converts dead bone graft to new, living tissue 2Gene therapy converts dead bone graft to new, living tissue 3Gene therapy converts dead bone graft to new, living tissue 4Leukemia Drug Breakthrough Study In New England Journal Of Medicine 2NYU researchers simulate molecular biological clock 2
... 1-D PAGE Cleavable ICAT ... Targeted Protein ID and ... Gel Electrophoresis (PAGE), isotope-coded ... cleavable-linker technology to facilitate ...
Supplemental reagent for annexin V assay....
Antibody Purification Specificity: Antibody Purification ...
Large-fragment, single-stranded carrier DNA of the highest quality, perfectly suited for all types of yeast transformation....
Biology Products: